barinthuslogo.jpg
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
September 24, 2024 08:00 ET | Barinthus Biotherapeutics
Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease
ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors
September 17, 2024 08:00 ET | ImmuneSensor Therapeutics
Composition and methods patent granted claims covering compounds for treating broad range of inflammatory and autoimmune diseases and built on foundational intellectual property for the discovery of...
ImmuneSensor_Resize.png
ImmuneSensor Therapeutics Appoints Veteran Biopharma Executive, Thomas W. Dubensky, Jr., Ph.D., as Chief Executive Officer
May 01, 2024 08:00 ET | ImmuneSensor Therapeutics
DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of best-in-class small molecule inhibitors and agonists of the...
barinthuslogo.jpg
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer
May 01, 2024 07:00 ET | Barinthus Biotherapeutics
Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer.
Barinthus Bio Product Pipeline
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
January 05, 2024 16:01 ET | Barinthus Biotherapeutics
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones
22157.jpg
Immunology Collaboration and Licensing Agreements Analysis Report 2023
November 17, 2023 06:13 ET | Research and Markets
Dublin, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The "Immunology Collaboration and Licensing Deals 2016-2023" report has been added to ResearchAndMarkets.com's offering.Immunology Collaboration and...
logo.jpg
Cyrex Announces Innovative New Immunophenotyping Test Panel, The Lymphocyte MAP™
July 21, 2021 09:00 ET | Cyrex Laboratories
PHOENIX, July 21, 2021 (GLOBE NEWSWIRE) -- Cyrex Laboratories, a clinical laboratory specializing in functional immunology and autoimmunity, today announced The Lymphocyte MAP™, which is the result...
Nurix.png
Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease
June 02, 2021 07:00 ET | Nurix Therapeutics, Inc.
Orally available NX-5948 is a potent selective degrader of Bruton’s Tyrosine Kinase (BTK) without IMiD activity Data were presented at the European Alliance of Associations for Rheumatology (EULAR)...
Beyond Celiac Awards
Beyond Celiac Awards Nearly $450,000 in Research Grants for Groundbreaking Studies on Celiac Disease
August 16, 2019 08:51 ET | Beyond Celiac
Philadelphia, PA, Aug. 16, 2019 (GLOBE NEWSWIRE) -- Beyond Celiac, the leading research-driven celiac disease organization working to drive diagnosis, advance research and accelerate the discovery...
Last Chance to Regis
Last Chance to Register: Beyond Celiac Global Webinar
October 04, 2018 14:53 ET | Beyond Celiac
Philadelphia, PA, Oct. 04, 2018 (GLOBE NEWSWIRE) -- Thousands have registered for the upcoming live webcast of the Second Annual Beyond Celiac Global Research Symposium. Others who are interested...